Formycon AG Logo

Formycon AG

ISIN

DE000A1EWVY8

Ticker

FYB

Sector

Health Care

Sub-Industry

Biotechnology

Country

Germany

Year Founded

1999

About Formycon AG

Company Description

Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market.

Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval.

We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.

Headcount

171

Served Area

Worldwide

Headquarters

Fraunhoferstraße 15
82152, Martinsried/Planegg
Germany

Filings & Publications

  • Consolidated Report 2021 - Q4 English 🇬🇧
  • Consolidated Report 2022 - Q2 English 🇬🇧

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.04.2024 Mikulcik, Dr. Marc Close relation Buy EUR 48,000.00
24.04.2024 Glombitza, Dr. Stefan Board Buy EUR 97,444.00

Capital Markets Information

ISIN

DE000A1EWVY8

LEI

39120005TZ76GQOY8Z19

Sub-Industry

Biotechnology

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.